Harvard Bioscience of Holliston reported a $1.4 million loss amid lower first-quarter revenues of $25.8 million, a slight drop of about 0.5 percent from $25.9 million in the same period of 2014, the life sciences manufacturer said.
Marlborough-based Boston Scientific Corp. reported adjusted first-quarter earnings of 21 cents per share Tuesday, a penny higher than for the first quarter of 2014, and at the high end of the company's projection of 19 to 21 cents.
Ashland biomedical device maker BioSurfaces Inc. has kept a relatively low profile through much of its 12-year history. But new developments are creating some noteworthy buzz for the small company and its portfolio of products designed to treat renal, heart and vascular diseases.
Biomedical device maker BioSurfaces Inc. of Ashland has been named the state's Microenterprise of the Year for 2015. The award was announced Monday by the Massachusetts office of the U.S. Small Business Administration (SBA).
A drug being developed by RXi Pharmaceuticals of Marlborough to treat patients with malignant melanoma has secured “orphan” status from the federal government, allowing RXi to seek more incentives to bring it to market, the company announced.
The CEO at biotech firm Harvard Apparatus Regenerative Technology (HART) of Holliston has resigned, replaced on an interim basis by CFO Thomas McNaughton, the company announced.
Framingham-based medical device maker Arch Therapeutics said a third-party, pre-clinical study had obtained favorable data for its surgical product, AC5 Surgical Hemostatic Device.
Boston Scientific has aligned itself with a Chinese company that will help the Marlborough-based medical device manufacturer reach out to more doctors in that country who remove stones from patients' bile ducts.
Convergent Dental of Natick, a privately held dental equipment and technology company, has entered into a distribution partnership for its dental laser product, Solea.